1203 related articles for article (PubMed ID: 15456468)
1. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
Jankowski JA; Anderson M
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and treatment of Barrett's oesophagus. A general survey.
Petrakis IE; Sciacca V; Iascone C
Acta Chir Belg; 2001; 101(2):53-8. PubMed ID: 11396051
[TBL] [Abstract][Full Text] [Related]
3. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation.
Morris CD; Byrne JP; Armstrong GR; Attwood SE
Br J Surg; 2001 Oct; 88(10):1357-62. PubMed ID: 11578292
[TBL] [Abstract][Full Text] [Related]
4. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
5. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
6. Management of Barrett's esophagus free of dysplasia.
DeMeester SR
Semin Thorac Cardiovasc Surg; 1997 Jul; 9(3):279-84. PubMed ID: 9263346
[TBL] [Abstract][Full Text] [Related]
7. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
8. Acid suppression and chemoprevention in Barrett's oesophagus.
Raj A; Jankowski J
Dig Dis; 2004; 22(2):171-80. PubMed ID: 15383758
[TBL] [Abstract][Full Text] [Related]
9. Should patients with Barrett's oesophagus be kept under surveillance? The case for.
Armstrong D
Best Pract Res Clin Gastroenterol; 2008; 22(4):721-39. PubMed ID: 18656826
[TBL] [Abstract][Full Text] [Related]
10. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma.
Tsibouris P; Hendrickse MT; Isaacs PE
Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913
[TBL] [Abstract][Full Text] [Related]
11. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.
Anderson LA; Johnston BT; Watson RG; Murphy SJ; Ferguson HR; Comber H; McGuigan J; Reynolds JV; Murray LJ
Cancer Res; 2006 May; 66(9):4975-82. PubMed ID: 16651456
[TBL] [Abstract][Full Text] [Related]
12. Review article: prevalence of Barrett's oesophagus and metaplasia at the gastro-oesophageal junction.
Sharma P
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():48-54; discussion 61-2. PubMed ID: 15456464
[TBL] [Abstract][Full Text] [Related]
13. Cancer risk in Barrett's oesophagus.
Dias Pereira A; Suspiro A; Chaves P
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):915-8. PubMed ID: 18049157
[TBL] [Abstract][Full Text] [Related]
14. Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?
Fitzgerald RC
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i21-6. PubMed ID: 15711004
[TBL] [Abstract][Full Text] [Related]
15. Barrett's esophagus and risk of esophageal adenocarcinoma.
Cossentino MJ; Wong RK
Semin Gastrointest Dis; 2003 Jul; 14(3):128-35. PubMed ID: 14653412
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.
Wolfsen HC; Hemminger LL; Wallace MB; Devault KR
Aliment Pharmacol Ther; 2004 Nov; 20(10):1125-31. PubMed ID: 15569115
[TBL] [Abstract][Full Text] [Related]
17. The evidence base of proton pump inhibitor chemopreventative agents in Barrett's esophagus--the good, the bad, and the flawed!
Leedham S; Jankowski J
Am J Gastroenterol; 2007 Jan; 102(1):21-3. PubMed ID: 17266685
[TBL] [Abstract][Full Text] [Related]
18. Barrett's oesophagus: the new endoscopic modalities have a future.
Deviere J
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i33-7. PubMed ID: 15711006
[TBL] [Abstract][Full Text] [Related]
19. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Cooper BT; Chapman W; Neumann CS; Gearty JC
Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
[TBL] [Abstract][Full Text] [Related]
20. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
Quera R; O'Sullivan K; Quigley EM
Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
